Heptares co-founder Fiona Marshall grabs the helm at Merck's upcoming UK drug discovery center
In a boost to its planned $1.3 billion UK drug research hub and headquarters, Merck announced today that it has recruited the noted British scientist and biotech exec Fiona Marshall to the top job at the center, which is expected to open in London in 2020.
The Heptares co-founder resigned from the EVP and CSO positions at parent company Sosei last week, making waves in the G protein-coupled receptors-targeting biotech that she helped create more than 10 years ago. An expert in GPCR biology, Marshall led the first group to show that GPCRs could form heterodimers and has played advisory roles in research organizations such as Alzheimer’s Research UK and Francis Crick Institute.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.